

Anna C Pavlick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/999403/publications.pdf>

Version: 2024-02-01

110
papers

6,485
citations

172457

29
h-index

71685

76
g-index

110
all docs

110
docs citations

110
times ranked

10905
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 372, 2006-2017.	27.0	2,489
2	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. <i>New England Journal of Medicine</i> , 2018, 379, 722-730.	27.0	983
3	MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	425
4	Intra- and Inter-Tumor Heterogeneity of BRAFV600E Mutations in Primary and Metastatic Melanoma. <i>PLoS ONE</i> , 2012, 7, e29336.	2.5	250
5	Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study. <i>Lancet Oncology</i> , The, 2014, 15, 954-965.	10.7	225
6	Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 4371-4380.	1.6	203
7	Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2656-2666.	1.6	145
8	Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1692-1704.	10.7	129
9	Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. , 2020, 8, e000775.		113
10	Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors. <i>Journal of Translational Medicine</i> , 2018, 16, 82.	4.4	98
11	Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With Pembrolizumab. <i>JAMA Dermatology</i> , 2017, 153, 299.	4.1	88
12	A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma. <i>Investigational New Drugs</i> , 2016, 34, 439-449.	2.6	86
13	Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma. <i>Cancer Immunology Research</i> , 2015, 3, 278-287.	3.4	81
14	Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2 including anti-PD-1.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2518-2518.	1.6	71
15	Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9501-9501.	1.6	70
16	Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). <i>Neuro-Oncology</i> , 2021, 23, 1961-1973.	1.2	66
17	Sensitivity of plasma BRAF^{mutant} and NRAS^{mutant} cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression. <i>Molecular Oncology</i> , 2016, 10, 157-165.	4.6	63
18	Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436). <i>Clinical Cancer Research</i> , 2014, 20, 4449-4458.	7.0	56

#	ARTICLE	IF	CITATIONS
19	The State of Melanoma: Emergent Challenges and Opportunities. <i>Clinical Cancer Research</i> , 2021, 27, 2678-2697.	7.0	53
20	Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases. <i>Journal of Neuro-Oncology</i> , 2016, 127, 607-615.	2.9	51
21	Identification of Metastasis-Suppressive microRNAs in Primary Melanoma. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	47
22	Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma. <i>Cancer Immunology Research</i> , 2020, 8, 70-80.	3.4	47
23	A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. <i>Cancer</i> , 2019, 125, 1113-1123.	4.1	45
24	Frontline Therapy for <i>BRAF</i> -Mutated Metastatic Melanoma: How Do You Choose, and Is There One Correct Answer?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 564-571.	3.8	42
25	Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 897-905.	4.2	38
26	A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 47-58.	2.6	34
27	Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma. <i>Future Oncology</i> , 2019, 15, 349-358.	2.4	34
28	Immunotherapy to treat malignancy in patients with pre-existing autoimmunity. , 2020, 8, e000356.		34
29	Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research. <i>American Journal of Translational Research (discontinued)</i> , 2009, 1, 35-43.	0.0	33
30	Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutant Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 46-53.	7.0	32
31	Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10006-10006.	1.6	32
32	A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600E ⁺ Mutant Solid Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 22-32.	7.0	30
33	Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 803-810.	2.3	25
34	First-line immunotherapy versus targeted therapy in patients with <i>BRAF</i> -mutant advanced melanoma: a real-world analysis. <i>Future Oncology</i> , 2021, 17, 689-699.	2.4	21
35	Decreased cytotoxic T cells and TCR clonality in organ transplant recipients with squamous cell carcinoma. <i>Npj Precision Oncology</i> , 2020, 4, 13.	5.4	20
36	Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in <i>BRAF</i> ^{V600E} melanoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8503-8503.	1.6	19

#	ARTICLE	IF	CITATIONS
37	Genetic associations of the interleukin locus at 1q32.1 with clinical outcomes of cutaneous melanoma. <i>Journal of Medical Genetics</i> , 2015, 52, 231-239.	3.2	17
38	TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma Tumors. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1609-1618.e7.	0.7	14
39	An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: Initial results from the skin cancer cohorts.. <i>Journal of Clinical Oncology</i> , 2020, 38, e22050-e22050.	1.6	14
40	A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 627 119-125.	1.4	12
41	MAGEA3 Expression in Cutaneous Squamous Cell Carcinoma Is Associated with Advanced Tumor Stage and Poor Prognosis. <i>Journal of Investigative Dermatology</i> , 2017, 137, 775-778.	0.7	12
42	Health-related quality of life (HRQL) in patients with advanced cutaneous squamous cell carcinoma (CSCC) treated with cemiplimab: Post hoc exploratory analyses of a phase II clinical trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10033-10033.	1.6	11
43	Evaluating the safety of anti-CTLA-4 therapy in the elderly with unresectable melanoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9063-9063.	1.6	9
44	A phase II study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 109-109.	1.6	8
45	Updated results from the skin cancer cohorts from an ongoing phase 1/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9553-9553.	1.6	8
46	Chemotherapy approaches to melanoma. <i>Dermatologic Clinics</i> , 2002, 20, 709-712.	1.7	7
47	Current concepts and approaches to merkel cell carcinoma. <i>Archives of Dermatological Research</i> , 2021, 313, 129-138.	1.9	7
48	Immunomodulatory germline variation associated with the development of multiple primary melanoma (MPM). <i>Scientific Reports</i> , 2019, 9, 10173.	3.3	6
49	Germline genetic determinants of immunotherapy response in metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3004-3004.	1.6	6
50	Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9522-9522.	1.6	6
51	Evidence-Based Consensus Recommendations for the Evolving Treatment of Patients with High-Risk and Advanced Cutaneous Squamous Cell Carcinoma. <i>JID Innovations</i> , 2021, 1, 100045.	2.4	5
52	Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2528-2528.	1.6	5
53	The relationship between obesity and immunotherapy: It's complicated.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9562-9562.	1.6	4
54	Preclinical and clinical studies of a class I/IV HDAC inhibitor, mocetinostat, in melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10052-10052.	1.6	4

#	ARTICLE	IF	CITATIONS
55	P865â€¦Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies â€œ independent review committee data update. , 2020, , .		3
56	Abstract LB180: Clinical biomarker studies with two fusion-enhanced versions of oncolytic HSV (RP1) Tj ETQq0 0 0 rgBT /Overlock 10 Tf activation. Cancer Research, 2021, 81, LB180-LB180.	0.9	3
57	Ipilimumab retreatment following induction therapy: The expanded access program (EAP) experience.. Journal of Clinical Oncology, 2013, 31, 9041-9041.	1.6	3
58	Metabolic tumor burden for prediction of overall survival following combined BRAF/MEK inhibition in patients with advanced BRAF mutant melanoma.. Journal of Clinical Oncology, 2014, 32, 9006-9006.	1.6	3
59	Predictive biomarkers of ipilimumab toxicity in metastatic melanoma.. Journal of Clinical Oncology, 2017, 35, 9559-9559.	1.6	3
60	Prediction of response and toxicity to immune checkpoint inhibitor therapies (ICI) in melanoma using deep neural networks machine learning.. Journal of Clinical Oncology, 2018, 36, 9529-9529.	1.6	3
61	Using machine learning algorithms to predict response and toxicity to immune checkpoint inhibitors (ICIs) in melanoma patients.. Journal of Clinical Oncology, 2019, 37, 2581-2581.	1.6	3
62	A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission.. Journal of Clinical Oncology, 2019, 37, 9538-9538.	1.6	3
63	Genetic variation in immunomodulatory genes as markers of melanoma recurrence-free and overall survival.. Journal of Clinical Oncology, 2013, 31, 9021-9021.	1.6	3
64	Somatic and germline analyses of a long term melanoma survivor with a recurrent brain metastasis. BMC Cancer, 2015, 15, 926.	2.6	2
65	Safety data from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).. Journal of Clinical Oncology, 2016, 34, 9525-9525.	1.6	2
66	Autoimmune genetic variants as germline biomarkers of response in melanoma immunotherapy treatment.. Journal of Clinical Oncology, 2018, 36, 3079-3079.	1.6	2
67	Gut microbiome and immunotherapy response in melanoma patients.. Journal of Clinical Oncology, 2018, 36, 9575-9575.	1.6	2
68	Bone metastasis to predict treatment response rate and overall survival of patients with metastatic melanoma.. Journal of Clinical Oncology, 2018, 36, e21585-e21585.	1.6	2
69	Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144,) Tj ETQq1 1 0.784314 rgBT /Overlock 11 systemic therapy.. Journal of Clinical Oncology, 2019, 37, 136-136.	1.6	2
70	Immunotherapy efficacy and safety in elderly cutaneous malignancy patients.. Journal of Clinical Oncology, 2018, 36, e21524-e21524.	1.6	2
71	MLTI-03. FIRST-LINE STEREOTACTIC RADIOSURGERY COMBINED WITH SYSTEMIC TARGETED AND IMMUNE CHECKPOINT INHIBITOR THERAPY IN MELANOMA PATIENTS WITH NEWLY DIAGNOSED BRAIN METASTASES. Neuro-Oncology Advances, 2019, 1, i14-i15.	0.7	1
72	Phase I/II study of the TLR3 agonist poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 vg in patients with melanoma.. Journal of Clinical Oncology, 2014, 32, TPS9119-TPS9119.	1.6	1

#	ARTICLE	IF	CITATIONS
73	Pharmacodynamic evaluation of pCDC2 as the target engagement biomarker to assess activity of MK-1775 a Wee1 tyrosine kinase inhibitor.. Journal of Clinical Oncology, 2012, 30, e13598-e13598.	1.6	1
74	Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma.. Journal of Clinical Oncology, 2014, 32, 9086-9086.	1.6	1
75	Clinical outcome and CD4+ differentiation in anti-CTLA-4/radiation and anti-CTLA-4/steroid therapy.. Journal of Clinical Oncology, 2014, 32, 3019-3019.	1.6	1
76	Targeting EZH2 in acral lentiginous melanoma (ALM).. Journal of Clinical Oncology, 2017, 35, 9534-9534.	1.6	1
77	Primary melanoma histologic subtype (HS) impacts melanoma specific survival (MSS) and response to systemic therapy.. Journal of Clinical Oncology, 2017, 35, 9577-9577.	1.6	1
78	Response to immune checkpoint inhibitor (ICI) rechallenge after high-grade immune related adverse events (irAE) in patients (pts) with metastatic melanoma (MM).. Journal of Clinical Oncology, 2020, 38, 10045-10045.	1.6	1
79	Using machine learning to predict immunotherapy response in advanced melanoma.. Journal of Clinical Oncology, 2020, 38, 10010-10010.	1.6	1
80	658â€¦Toxicities of single agent and combination immune checkpoint inhibitors in patients with pre-existing autoimmune diseases. , 2020, , .		1
81	Outcomes in patients with resected stage IIIA melanoma treated with adjuvant nivolumab or monitored with observation: A real-world study.. Journal of Clinical Oncology, 2022, 40, e21534-e21534.	1.6	1
82	Treatment of Metastatic Hormone Refractory Prostate Cancer with Ketoconazole, Hydrocortisone, and Cyclophosphamide. Prostate Journal, 2001, 3, 71-75.	0.2	0
83	Dabrafenib for the treatment of melanoma. Expert Opinion on Orphan Drugs, 2015, 3, 1075-1084.	0.8	0
84	Gamma Knife Radiosurgery and Immunotherapy as Primary Treatment for a Malignant Tumor of the Cranial Base Beginning as Lentigo Maligna: A Case Report. Practical Radiation Oncology, 2019, 9, e608-e612.	2.1	0
85	The melanoma risk loci as determinants of melanoma prognosis.. Journal of Clinical Oncology, 2012, 30, 8557-8557.	1.6	0
86	MicroRNA alterations associated with <i>BRAF</i> status in melanoma.. Journal of Clinical Oncology, 2012, 30, 8565-8565.	1.6	0
87	Early alterations of microRNA expression to predict and modulate melanoma metastasis.. Journal of Clinical Oncology, 2012, 30, 8550-8550.	1.6	0
88	Prognostic value of mitosis-specific antibodies and computer image analysis in calculating mitotic rate in melanoma.. Journal of Clinical Oncology, 2012, 30, e19003-e19003.	1.6	0
89	TILs in metastatic melanoma tumors: A biomarker for immunotherapy?. Journal of Clinical Oncology, 2012, 30, 8589-8589.	1.6	0
90	Impact of age on treatment of primary melanoma patients.. Journal of Clinical Oncology, 2013, 31, 9054-9054.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Analysis of plasma-based <i>BRAF</i> and <i>NRAS</i> mutation detection in patients with stage III and IV melanoma.. Journal of Clinical Oncology, 2013, 31, 9023-9023.	1.6	0
92	Molecular underpinning of melanoma histologic subtypes in the metastatic setting.. Journal of Clinical Oncology, 2014, 32, e20053-e20053.	1.6	0
93	Integration of melanoma genotyping in clinical care.. Journal of Clinical Oncology, 2014, 32, 9095-9095.	1.6	0
94	Matrix metalloproteinase-23 as a new immunotherapeutic checkpoint target in melanoma.. Journal of Clinical Oncology, 2014, 32, 3030-3030.	1.6	0
95	Dissecting the effect of age on immune response in melanoma patients.. Journal of Clinical Oncology, 2014, 32, 9058-9058.	1.6	0
96	The genetic variants in interleukin locus at 1q32.1 as markers of melanoma survival.. Journal of Clinical Oncology, 2014, 32, 9094-9094.	1.6	0
97	Association of natural killer (NK) cell exhaustion with melanoma progression.. Journal of Clinical Oncology, 2014, 32, 9099-9099.	1.6	0
98	Droplet digital PCR monitoring of BRAF and NRAS plasma DNA as biomarkers of treatment response in stage IV melanoma.. Journal of Clinical Oncology, 2014, 32, 9019-9019.	1.6	0
99	Expression quantitative trait loci (eQTLs) as germline determinants of melanoma immunotherapy response.. Journal of Clinical Oncology, 2017, 35, 3017-3017.	1.6	0
100	Retrospective review of metastatic uveal melanoma (mUM) at NYU Perlmutter Cancer Center (NYU-PCC).. Journal of Clinical Oncology, 2017, 35, e21040-e21040.	1.6	0
101	Association of increased somatic mutations in metastatic melanoma patients with clinical outcome.. Journal of Clinical Oncology, 2018, 36, e21568-e21568.	1.6	0
102	First-line stereotactic radiosurgery combined with systemic targeted and immune checkpoint inhibitor therapy in melanoma patients with newly diagnosed brain metastases.. Journal of Clinical Oncology, 2019, 37, e13577-e13577.	1.6	0
103	Real-world Merkel cell carcinoma outcomes from a tertiary care center.. Journal of Clinical Oncology, 2019, 37, e14098-e14098.	1.6	0
104	Outcomes in MAGE+ cutaneous squamous cell carcinoma with perineural invasion treated with surgery followed by postoperative radiation therapy.. Journal of Clinical Oncology, 2019, 37, e21043-e21043.	1.6	0
105	Transforming a cancer center into a high reliability organization.. Journal of Clinical Oncology, 2019, 37, 234-234.	1.6	0
106	Salvage chemotherapy in the treatment of metastatic melanoma after progression on immunotherapy.. Journal of Clinical Oncology, 2020, 38, e22019-e22019.	1.6	0
107	Effect of administration of systemic steroids on survival benefit associated with immunotherapy-induced skin toxicity.. Journal of Clinical Oncology, 2020, 38, e22046-e22046.	1.6	0
108	Novel blood-based biomarker predicting severe toxicity in melanoma anti-CTLA-4 immunotherapy treatment.. Journal of Clinical Oncology, 2020, 38, 3077-3077.	1.6	0

#	ARTICLE	IF	CITATIONS
109	426â€¦MK-3475-U02: Phase 1/2 study of investigational agents with or without pembrolizumab versus pembrolizumab monotherapy in melanoma. , 2020, , .		0
110	Innovations in the treatment of melanoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2004, 2 Suppl 3, S-34-7.	4.9	0